Dr. Younes on Brentuximab Plus AVD vs ABVD in Classical Hodgkin Lymphoma

Anas Younes, MD
Published Online: Thursday, Aug 28, 2014
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the ongoing Echelon-1 study in classical Hodgkin lymphoma.

The current standard of care for patients with classical Hodgkin lymphoma is ABVD. A phase I trial that combined AVD with brentuximab vedotin showed promising safety and efficacy results.

The Echelon-1 study is a large, randomized trial aiming to compare ABVD with AVD plus brentuximab. The primary endpoint of the trial is modified progression-free survival: death, progression, receipt of chemotherapy or radiotherapy by patients not in complete response after completing front-line therapy.

Results of this trial could change practice, Younes says.

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the ongoing Echelon-1 study in classical Hodgkin lymphoma.

The current standard of care for patients with classical Hodgkin lymphoma is ABVD. A phase I trial that combined AVD with brentuximab vedotin showed promising safety and efficacy results.

The Echelon-1 study is a large, randomized trial aiming to compare ABVD with AVD plus brentuximab. The primary endpoint of the trial is modified progression-free survival: death, progression, receipt of chemotherapy or radiotherapy by patients not in complete response after completing front-line therapy.

Results of this trial could change practice, Younes says.

Online CME Activities
TitleExpiration DateCME Credits
2nd Annual Miami Lung Cancer Conference™ Medical Crossfire® Case DiscussionMay 31, 20163.75
Medical Crossfire®: The JAK-STAT Pathway as a Mediator of Onco-InflammationMay 31, 20161.5